Related Experiment Video
Updated: Nov 1, 2025
A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors
Published on: April 29, 2022
Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer
Qiuyue Zhang1,2, Zhongjiao Fan1,2, Lianshan Zhang3
1State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Abstract:
Among numerous posttranslational regulation patterns, phosphorylation is reversibly controlled by the balance of kinases and phosphatases. The major form of cellular signaling involves the reversible phosphorylation of proteins on tyrosine, serine, or threonine residues. However, altered phosphorylation levels are found in diverse diseases, including cancer, making kinases and phosphatases ideal drug targets. In contrast to the success of prosperous kinase inhibitors, design of small molecules targeting phosphatase is struggling due to past bias and difficulty. This is especially true for serine/threonine phosphatases, one of the largest phosphatase families. From this perspective, we aim to provide insights into serine/threonine phosphatases and the small molecules targeting these proteins for drug development, especially in cancer. Through highlighting the modulation strategies, we aim to provide basic principles for the design of small molecules and future perspectives for the application of drugs targeting serine/threonine phosphatases.
Insights
Altered protein phosphorylation is implicated in diseases like cancer. This study explores serine/threonine phosphatases and small molecule drug development strategies for targeting these enzymes, particularly in cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Protein phosphorylation, regulated by kinases and phosphatases, is crucial for cellular signaling.
- Dysregulated phosphorylation is linked to various diseases, notably cancer, highlighting kinases and phosphatases as drug targets.
- Developing small molecule inhibitors for phosphatases, especially serine/threonine phosphatases, faces challenges compared to kinase inhibitors.
Purpose of the Study:
- To provide insights into serine/threonine phosphatases.
- To explore small molecules targeting serine/threonine phosphatases for drug development in cancer.
- To outline modulation strategies and principles for designing small molecule drugs targeting these enzymes.
Main Methods:
- Literature review of serine/threonine phosphatases.
- Analysis of existing small molecule inhibitors and their mechanisms.
- Discussion of drug design principles and modulation strategies.
Main Results:
- Serine/threonine phosphatases represent a significant target family in drug development.
- Challenges exist in designing effective small molecules for phosphatases due to historical biases and inherent difficulties.
- Specific modulation strategies can guide the development of targeted therapies.
Conclusions:
- Targeting serine/threonine phosphatases holds therapeutic potential, especially in oncology.
- Overcoming design challenges requires focused strategies and a deeper understanding of phosphatase biology.
- Future drug development should consider novel approaches for effective serine/threonine phosphatase modulation.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:02Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
01:22Amplifying Signals via Enzymatic Cascade
02:34Inhibition of Cdk Activity